17537-76-7

Basic information

• Product Name: 5-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one
• Synonyms: 5-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one
• CAS NO: 17537-76-7
• Molecular Formula: C₁₃H₁₀N₂O₂S
• Molecular Weight: 258.2957
• Mol File: 17537-76-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 487.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• PKA: 9.58±0.20(Predicted)
• CAS DataBase Reference: 5-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one(17537-76-7)
• EPA Substance Registry System: 5-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one(17537-76-7)

Safety Data

• Hazardous Substances Data: 17537-76-7(Hazardous Substances Data)

Upstream product

• 15854-11-2 ethyl 2-amino-4-(4'-methoxyphenyl) thiophene-3-carboxylate 
• 77287-34-4 formamide 
• 123-11-5 4-methoxy-benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 16712-16-6 ammonium formate 
• 13455-80-6 2-cyano-3-(4-methoxy-phenyl)-crotonic acid ethyl ester 

Downstream Products

• 312584-53-5 4-chloro-5-(4-methoxyphenyl)thieno[2,3-d]pyrimidine 
• 1639810-22-2 C₁₆H₁₄N₂O₄S 
• 1018281-39-4 4-piperazin-1-yl-5-(4-methoxy-phenyl)-thieno[2,3-d]pyrimidine 
• 929417-75-4 N-(4-(5-(4-methoxy-phenyl)-7H-thieno[2,3-d]pyrimidin-4-ylamino)-benzenesulfonyl)-acetamide 

Relevant articles and documents

Identification of 4-methoxythieno[2,3-d]pyrimidines as FGFR1 inhibitors

Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds binding with the ATP-acceptor site was determined using molecular docking methods and the dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated.

Novel 4-oxothienopyrimidinyl propanoic acid derivatives as AMPactivated protein kinase (AMPK) activators

Adenosine 5′-monophosphate (AMP) activated protein kinase (AMPK) is a highly conserved sensor of cellular energy. AMPK has been recognized as a key regulator of mammalian metabolic function and has emerged as an attractive target for the treatment of meta

THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS

The present invention provides thienopyrimidine compounds which are potasium channels inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also provided.